Biosimilars

Pfizer’s Remicade biosimilar will now be reimbursed by Medicare.

The rule builds on the FDA’s ongoing effort to encourage complete postmarketing safety data on various biologic and device products.

Both combination product applicants and constituent part applicants are required to comply with postmarketing safety reporting rules.

Biosimilar erythropoiesis-stimulating agent epoetin was well-tolerated and efficacious in the treatment of geriatric patients with chemotherapy-induced anemia.

Top articles of 2016 on Specialty Pharmacy Times.

The biosimilar epoetin was well-tolerated in elderly cancer patient populations.

Results from an interim analysis show ritixumab biosimilar to be equivalent to reference product.

Etanercept found equally as effective as Enbrel in treating plaque psoriasis.

Etanercept found equally effective treating plaque psoriasis compared with Enbrel.

Biosimilars can provide an easily accessible, low cost treatment option for patients with rheumatoid arthritis.

Regulatory perspectives presented at ACR on biosimilars entering the market convey the importance of crafting antibodies to our own purposes.

Amgen will present findings from clinical studies of both branded and investigational drugs.

A majority of specialty physicians have knowledge gaps when it comes to biosimilars.

Physicians may lack knowledge about fundamental information regarding biosimilars.

Biosimilars have been in the news quite a bit lately. Here’s an update on some of the big developments related to biosimilar development, approval, and regulations

Inflectra is the first biosimilar monoclonal antibody approved by the FDA.

Top news of the day from across the healthcare landscape.

Top news of the day from across the health care landscape.

Acceptance and utilization of biosimilar drugs still in need of improvement within specialty pharmacy.

Merck launches Biosimilars Clarified to illustrate potential of cost-saving biologic drugs.

Health care practitioners need to prepare for myriad questions regarding biosimilars and follow-on biologic drugs as they enter the market.

Amgen’s Amjevita, a biosimilar to Humira, approved for variety of anti-inflammatory diseases.

Biosimilars have become increasingly popular in the last few years.

Erelzi, an etanercept biosimilar, was approved for rheumatoid arthritis, plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and polyarticular juvenile idiopathic arthritis.

Sandoz has gained FDA-approval for Erelzi, an etanercept biosimilar.

Top news of the week from Specialty Pharmacy Times.

Pharmacists prefer a distinct name for biosimilars with a nonproprietary name and a designated suffix.

The confidence of pharmacists dispensing biosimilars along with varying opinions on naming conventions influence uptake of interchangeable biologic drugs.

A patent for a rheumatoid arthritis drug was ruled invalid, but Johnson & Johnson plans to appeal the decision.